Figitumumab

{{Infobox drug | Watchedfields = changed | verifiedrevid = 470604125 | IUPAC_name = (2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2-amino-3-phenylpropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoic acid | image = Figitumumab structure.png | width = 250 | tradename = | Drugs.com = | pregnancy_category = | routes_of_administration = Intravenous | ATC_prefix = None | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = | PubChem = | DrugBank = | ChemSpider = | UNII = | KEGG = | ChEMBL = | synonyms = CP-751,871 }}

Figitumumab is an experimental monoclonal antibody designed for the treatment of cancer. It targets the insulin-like growth factor 1 receptor (IGF-1R), which plays a pivotal role in the growth of cancer cells. Figitumumab binds to IGF-1R and inhibits its activity, thereby potentially controlling the proliferation of cancer cells.

Mechanism of Action

Figitumumab works by binding to the extracellular domain of the IGF-1R, blocking the binding of the natural ligands, IGF-1 and IGF-2. This inhibition prevents the receptor from activating its intracellular signaling pathways, which are crucial for cancer cell growth, survival, and proliferation.

Clinical Trials

Figitumumab has been evaluated in various clinical trials for its effectiveness and safety in treating different types of cancers, including non-small cell lung cancer (NSCLC), prostate cancer, and breast cancer. However, the development of figitumumab was discontinued in later-stage trials due to insufficient efficacy and concerns over adverse effects.

Adverse Effects

During the clinical trials, figitumumab was associated with several adverse effects. Commonly reported side effects included hyperglycemia, fatigue, and neutropenia. The severity of these side effects varied among patients, influencing the overall tolerability of the treatment.

Development and Regulatory Status

As of the last update, figitumumab remains an investigational drug and has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for public use. Research and development by the sponsoring pharmaceutical company were halted, and the focus shifted to other potential therapies.

See Also

• Monoclonal antibodies in cancer therapy
• Targeted therapy
• Insulin-like growth factor